Dose-Dense ETC in Early BC

Article

A GermanAGO Group multicenter randomizedphase III trial by Volker J. Moebus, MD,et al has confirmed the benefit of dosedense(DD) ETC chemotherapy in highriskearly breast cancer.

SAN ANTONIO–A GermanAGO Group multicenter randomizedphase III trial by Volker J. Moebus, MD,et al has confirmed the benefit of dosedense(DD) ETC chemotherapy in highriskearly breast cancer (abstract 53). The1,284 patients enrolled had ≥ 4 positiveaxillary nodes (median, 8). DD therapycomprised 3 cycles of epirubicin (Ellence)at 150 mg/m2, paclitaxel (Taxol) at 225mg/m2, and cyclophosphamide (C) at2,500 mg/m2 q2wk with G-CSF support.Conventional therapy was 4 cycles of Eand C at standard dosages, followed by 4courses of T (at 175 mg/m2) q3wk. Morethan 80% of patients received theplanned number of cycles of therapy.

In the DD arm, the relapse-free survivalrate was 70%, vs 62% with conventionaltherapy (P = .029). Overall survivalwas 82% with DD therapy vs 77%with conventional dosing (P = .029). Atotal of 182 patients in the DD armrelapsed vs 226 patients on standardtherapy (HR 0.72, P = .00079). No severecardiotoxicity or unusual toxicitiesoccurred.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content